Literature DB >> 34626424

Investigating the Roles of Heparan Sulfate Structures in Alpha-Synuclein Aggregation in Cell Culture Models.

Anindita Roy1, Akila V Chalapathi1, Kuberan Balagurunathan2.   

Abstract

Glycosaminoglycans (GAGs), belonging to a family of negatively charged linear polysaccharides, have been found in the cores of amyloid inclusions such as Lewy bodies, which are the central pathological features in Parkinson's disease (PD), a neurodegenerative disease. Lewy bodies/neurites are mostly composed of α-synuclein protein (α-syn) aggregates. Recent studies have shown that α-syn aggregates can propagate via neurons in a prion-like fashion by seeding the endogenous cellular α-syn. Various GAGs, especially heparan sulfate (HS), have been shown to be very critical in the aggregation of α-syn. HS chains of heparan sulfate proteoglycans (HSPGs) mediate the uptake of α-syn aggregates and help seed intracellular accumulation and further neuronal spread. Methods that inhibit the binding of these aggregates to HSPG have been shown to decrease the aggregate uptake and propagation. Here, we describe a cell-based assay to screen inhibitors of HS and α-syn interactions.
© 2022. Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Aggregate; Glycosaminoglycan; Heparan sulfate; Heparin; Neurodegeneration; Parkinson’s disease; α-Synuclein

Mesh:

Substances:

Year:  2022        PMID: 34626424     DOI: 10.1007/978-1-0716-1398-6_60

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  21 in total

Review 1.  Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders.

Authors:  Byron Caughey; Peter T Lansbury
Journal:  Annu Rev Neurosci       Date:  2003-04-09       Impact factor: 12.449

2.  Cross-seeding effects of amyloid β-protein and α-synuclein.

Authors:  Kenjiro Ono; Ryoichi Takahashi; Tokuhei Ikeda; Masahito Yamada
Journal:  J Neurochem       Date:  2012-07-23       Impact factor: 5.372

3.  Addition of exogenous α-synuclein preformed fibrils to primary neuronal cultures to seed recruitment of endogenous α-synuclein to Lewy body and Lewy neurite-like aggregates.

Authors:  Laura A Volpicelli-Daley; Kelvin C Luk; Virginia M-Y Lee
Journal:  Nat Protoc       Date:  2014-08-14       Impact factor: 13.491

4.  The significance of the Lewy body in the diagnosis of idiopathic Parkinson's disease.

Authors:  W R Gibb; A J Lees
Journal:  Neuropathol Appl Neurobiol       Date:  1989 Jan-Feb       Impact factor: 8.090

5.  The human NACP/alpha-synuclein gene: chromosome assignment to 4q21.3-q22 and TaqI RFLP analysis.

Authors:  X Chen; H A de Silva; M J Pettenati; P N Rao; P St George-Hyslop; A D Roses; Y Xia; K Horsburgh; K Uéda; T Saitoh
Journal:  Genomics       Date:  1995-03-20       Impact factor: 5.736

Review 6.  Levodopa-induced-dyskinesias clinical features, incidence, risk factors, management and impact on quality of life.

Authors:  Alice Manson; Paola Stirpe; Anette Schrag
Journal:  J Parkinsons Dis       Date:  2012       Impact factor: 5.568

Review 7.  Management of motor and non-motor symptoms in Parkinson's disease.

Authors:  Fabienne Sprenger; Werner Poewe
Journal:  CNS Drugs       Date:  2013-04       Impact factor: 5.749

8.  α-Synuclein genetic variants predict faster motor symptom progression in idiopathic Parkinson disease.

Authors:  Beate Ritz; Shannon L Rhodes; Yvette Bordelon; Jeff Bronstein
Journal:  PLoS One       Date:  2012-05-15       Impact factor: 3.240

9.  The role of alpha-synuclein oligomerization and aggregation in cellular and animal models of Parkinson's disease.

Authors:  Oi Wan Wan; Kenny K K Chung
Journal:  PLoS One       Date:  2012-06-12       Impact factor: 3.240

Review 10.  Alpha-Synuclein Physiology and Pathology: A Perspective on Cellular Structures and Organelles.

Authors:  Luis D Bernal-Conde; Rodrigo Ramos-Acevedo; Mario A Reyes-Hernández; Andrea J Balbuena-Olvera; Ishbelt D Morales-Moreno; Rubén Argüero-Sánchez; Birgitt Schüle; Magdalena Guerra-Crespo
Journal:  Front Neurosci       Date:  2020-01-23       Impact factor: 4.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.